Skip to content

Objective evaluation for changes of dopamine transporter using PET with [18F]FE-PE2I among psychiatric illnesses.

Objective evaluation for changes of dopamine transporter using PET with [18F]FE-PE2I among psychiatric illnesses. - Evaluation for dopamine transporter using PET with [18F] FE-PE2I among psychiatric illnesses.

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
JPRN
Registry ID
JPRN-UMIN000006962
Enrollment
110
Registered
2012-01-01
Start date
2012-01-01
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

healthy adults, dementia with lewy body (DLB), schizophrenia, mood disorder, REM sleep behavior disorder (RBD), Attention deficit hyperactivity disorder (ADHD)

Interventions

PET, MRI, neuropsychological batteries, neurological examinations PET, MRI, neuropsychological batteries, neurological examinations PET, MRI, neuropsychological batteries, neurological examinations PE

Sponsors

Nippon Medical School
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Healthy adults - without past or current history of psychiatric illnesses illnesses groups - who met the diagnostic criteria of DLB, Schizophrenia, Mood disorder, RBD, or ADHD

Exclusion criteria

Exclusion criteria: Exclusion criteria: - With past or current history of serious medical illness and/or brain organic diseases - Subject who is contraindicated for the use of MRI - With past or current history of severe liver disease, kidney disease, heart disease, allergy, or severe drug allergy - Subjects who are judged as not suitable for participation in this study

Design outcomes

Primary

MeasureTime frame
Quantitative measurement of brain dopamine transporter binding

Secondary

MeasureTime frame
brain MRI

Countries

Japan

Contacts

Public ContactAmane Tateno, M.D., Ph.D.

Nippon Medical School Department of Neuropsychiatry

amtateno@nms.a.cjp03-3822-2131

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026